Key Highlights

  • Archer Materials Limited (ASX:AXE) has completed the Beta prototype of its point-of-care Biosensor blood-testing kit.
  • The company says the integrated kit delivers a result in about six minutes from a fingerprick sample.
  • The beta prototype is ready for external testing and for early Manufacturing design with specialist medical device contract manufacturers.
  • Lithium testing is the initial application, with discussions under way with tier-one clinical partners in Australia and internationally.

Archer Materials Limited (ASX:AXE), a company describing itself as a quantum technology business, has completed the beta prototype of its Biosensor point-of-care blood-testing device. The announcement, dated 19 November 2026, says the integrated kit brings together the cartridge, chip packaging, sensors, reader and readout electronics into a single testing workflow. The company said the milestone follows positive results from its earlier Alpha prototype.

What the Beta Prototype Includes

According to Archer, the beta prototype supports the complete testing workflow, from application of a blood sample through to analysis and a displayed result. The company says the result is available in about six minutes from fingerprick sample to result. The device is designed to be operated end to end by external users, which allows Archer to assess performance, sample handling, clinical workflows and usability outside its own laboratories.

The company’s earlier alpha prototype results were reported in an announcement dated 30 January 2026, and the beta work is presented as the next engineering step after that work.

Path to External Validation

With the beta prototype complete, Archer intends to move the program toward external testing, validation and clinical trials. The company says independent evidence of accuracy, reliability and ease of use in clinical settings will guide final product development and support future regulatory and commercial steps. It also expects the next phase to draw feedback from contract manufacturers and clinical partners.

Archer is in discussions with tier-one clinical partners in Australia and internationally to conduct external validation, including a comparison of its lithium testing application against established laboratory methods. Blood potassium testing is identified as a later application in the broader diagnostic pipeline.

Commercial Context and Caveats

Chief Executive Dr Simon Ruffell described the device as a highly sophisticated integrated medical device and said the next phase is about building evidence on how it performs in practical settings. The company describes lithium testing as the beachhead application, chosen on the basis of clinical customer feedback.

The announcement does not include clinical performance data from the beta prototype, timelines for regulatory submissions or any Revenue estimates. Those items depend on the external validation work and the clinical trial programs still to come.

Looking Ahead

The coming period will focus on external testing, the outcome of clinical partner discussions and initial manufacturing design with contract manufacturers. Whether the device moves from engineering milestone to clinical evidence will depend on those validation results.